ORIC
Live chart
What they do
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study.
For information only · Important disclosures
Grades vs sector
No sector grades for ORIC yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | -0.36 | -0.38 | -5.3% |
| 2026-05-04 | -0.32 | -0.34 | -6.0% |
| 2026-02-23 | -0.37 | -0.30 | +18.5% |
| 2025-11-13 | -0.40 | -0.33 | +17.5% |
| 2025-08-12 | -0.44 | -0.47 | -5.8% |
| 2025-05-05 | -0.50 | -0.42 | +16.8% |
| 2025-02-18 | -0.51 | -0.51 | -0.3% |
| 2024-11-12 | -0.47 | -0.49 | -3.9% |
Insider trades
$41.3K
$45.2K
$181.3K
$6.8K
$1.4K
$1.1M
$73.3K
$84.1K
Stats refreshed 2026-10-20 17:56:41 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026